search

Active clinical trials for "Ovarian Neoplasms"

Results 531-540 of 2005

Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers

BRCA1 Gene MutationBRCA2 Gene Mutation1 more

The purpose of this study is to determine whether an innovative preventive strategy, consisting of early salpingectomy upon completion of childbearing with delayed oophorectomy beyond current guideline age, improves menopause-related quality of life without significantly increasing ovarian cancer incidence in comparison to current standard salpingo-oophorectomy in female BRCA1/2 mutation carriers.

Active14 enrollment criteria

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed...

Ovarian CancerDrug Related Neoplasm/Cancer

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Not yet recruiting21 enrollment criteria

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Ovarian CancerFallopian Tube Cancer1 more

Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Not yet recruiting21 enrollment criteria

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Breast CancerOvarian Cancer2 more

This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

Active10 enrollment criteria

Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer...

Breast CancerColorectal Cancer7 more

This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial, renal, thyroid, and ovarian cancers, as well as multiple myeloma and non-Hodgkin Lymphoma. Overarching outcomes also include physical function and performance, muscle mass, quality of life, and health utilities.

Active18 enrollment criteria

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and...

Advanced Solid Tumors (Excluding Prostate Cancer)Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.

Active36 enrollment criteria

REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related...

Ovarian CancerFatigue2 more

This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.

Active12 enrollment criteria

Cost Utility of Radical Surgery in Ovarian Cancer

Ovarian Cancer

The purpose of this study is to investigate the medico-economic impact of adherence to INCa (National Cancer Institute) guidelines in ovarian cancer surgery by assessment of outcome in cost per Quality Adjusted Life Years (QALY).

Active13 enrollment criteria

Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients...

Ovarian CancerFallopian Tube Cancer1 more

There is a move towards personalized medicine in cancer care, and significant effort is underway to evaluate new targeted therapeutics for the treatment of ovarian cancer. One way to identify potential new drug targets is by screening a drug library to determine whether drugs in the library target key kinase or enzymatic sites in cellular signaling pathways. Previous preclinical work and pilot studies demonstrated that ketorolac (a type of non-steroidal anti-inflammatory drug) inhibits GTPase activity in ovarian cancer cells retrieved from the post-operative peritoneal cavity. The purpose of this study is to confirm that this inhibitory effect is ketorolac driven and not a specific effect of the post-operative peritoneal compartment.

Active31 enrollment criteria

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Ovarian Cancer

To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.

Not yet recruiting12 enrollment criteria
1...535455...201

Need Help? Contact our team!


We'll reach out to this number within 24 hrs